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MorbidityAbstract Objectives: We assessed whether at admission plasma circulating cell free mitochondrial
DNA (ccf-mtDNA) is related to injury severity and can predict morbidity and mortality in acute
trauma patients.
Patients and methods: Patients were evaluated at Emergency Department (ED) using Injury Sever-
ity Scale (ISS), but only patients required ICU admission were studied (Group B). At ED arrival,
blood samples were obtained for quantitative real-time PCR estimation of plasma level of
ccf-mtDNA. Study outcome was the correlation between morbidity and mortality and at admission
plasma ccf-mtDNA level and its predictability for morbidity and mortality. Ten healthy volunteers
gave blood samples as control group (Group B).
Results: Twenty-seven patients passed smooth ICU stay and were discharged alive (Group B1),
while 34 patients developed additional morbidities (Group B2) and 11 patients (18%) of Group
A2 died. Mean estimated plasma ccf-mtDNA levels were significantly higher in Group B than in
Group A, but patients of Group B1 had significantly lower ccf-mtDNA levels than patients of
Group B2. Patients developed adult respiratory distress syndrome (ARDS) had significantly higher
ccf-mtDNA levels than patients developed sepsis or acute myocardial infarction (AMI) with signif-
icantly higher levels in patients developed sepsis. Estimated plasma ccf-mtDNA levels at time of
admission showed positive significant correlation with morbidity rate. Odds ratio (OR) for relative
risk for development of additional morbidities in patients who had a high plasma ccf-mtDNA level
was 26.35. At admission plasma ccf-mtDNA levels in survivors were significantly lower than in non-
survivors, and OR was 4.0806. High plasma ccf-mtDNA showed high sensitivity as predictor for
ICU mortality.2.
566 A.A. Mohamed et al.Conclusion: High at ED admission plasma ccf-mtDNA levels could predict development of addi-
tional morbidities during ICU stay of acute trauma patients and showed high sensitivity for predic-
tion of their survival. Very high plasma ccf-mtDNA levels could predict patients liable to develop
ARDS.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Plasma DNA can be defined as fragments of DNA that are
detectable in the extracellular fluid. There are two types of
DNA present in the circulation, circulating cell free DNA
(ccfDNA) present in the plasma, which includes DNA packed
into nucleosomes from apoptotic cells or DNA associated with
circulating lymphocytes which is considered as a minor com-
ponent [1].
Concomitantly, fragments of mitochondrial DNA are
released into the bloodstream. In healthy individuals, the con-
centration of circulating cell free mitochondrial DNA (ccf-
mtDNA) is low, as dead cells are efficiently removed from
the circulation by phagocytes. Circulating cfDNA has a short
half-life and is removed mainly by the liver. Excessive accumu-
lation of ccf-mtDNA in the plasma may result from the release
of DNA caused by massive cell death, inefficient removal of
dying cells or a combination of both [2].
Circulating cf-mtDNA fragments induce direct activation
of polymorphonuclear neutrophils via Toll-like receptor-9
and formyl-peptide receptor-1 and a SIRS phenotype. The pre-
sumption of this reaction is based on the homology of mtDNA
with pathogen associated molecular patterns recognized as for-
eign by the body [3].
Concentrations of plasma ccf-mtDNA are increased in var-
ious diseases and have shown some prognostic value in many
patient groups, including critically ill patients. Pathophysiolog-
ical processes behind the need for mechanical ventilation and
the treatment itself could raise plasma levels of ccf-mtDNA [4].
Worldwide, injuries resulted in 4.8 million deaths in 2013,
an increase of 11.0% since 1990 [5]. Most of these deaths
occurred in low- and middle-income countries. World Health
Organization estimated that injury is responsible for more
deaths than HIV, malaria, and tuberculosis combined [6].
Plasma ccfDNA is a potential marker for trauma prognosis
especially death, after severe injury. Circulating cfDNA seems
to be connected with injury type and mode, open wounds and
surgical operations, which may be the primary reasons for
plasma cfDNA increase [7].
2. Aim of the study
We assessed whether at admission plasma circulating cell free
mitochondrial DNA (ccf-mtDNA) is related to injury severity
and can predict morbidity and mortality in acute trauma
patients admitted to ICU.
3. Patients and methods
The current study was conducted at Department of Anesthesia
and ICU at Kasr Al-Ini University Hospital since January
2013 till May 2014. After approval of the study protocol bythe Local Ethical Committee and obtaining written fully
informed consent from the nearest relative attending with the
patient, all patients with solitary or multiple trauma were
enrolled in the study. The study also included 10 sex- and
age-matched healthy volunteers to give blood samples as con-
trol for plasma ccf-mtDNA levels (Group A).
Collected data included age, gender, time lapsed since
trauma inflection and arrival to Emergency Department (ED),
and injury related data including site, multiplicity, type and
cause of trauma. All patients received first aid and resuscitative
measures and were clinically evaluated using the Abbreviated
Injury Scale (AIS) which is an anatomical injury scoring system
on a scale of 1–6 grades: 1 indicated minor, 2 indicated moder-
ate, 3 indicated serious, 4 indicated severe, 5 indicated critical
and 6 indicated non-survivable injury. Then, each injury was
allocated to one of six body regions including Head, Face,
Chest, Abdomen, Extremities and Pelvis, External and the high-
est AIS score in each body region is used. The 3 most severely
injured body regions have their score squared and added
together to produce the Injury Severity Scale (ISS) score. The
ISS provides an overall score for patients with multiple injuries
taking values from 0 to 75. If an injury is assigned an AIS of 6
(unsurvivable injury), the ISS score is automatically assigned
to score of 75. The ISS score is virtually the only anatomical
scoring system in use and correlates linearly with mortality,
morbidity, hospital stay and other measures of severity [8].
Only patients required admission to ICU either preopera-
tively or postoperatively were included in the study as Group
B. Patients who passed smooth ICU stay without development
of additional morbidities and were discharged alive were
grouped as Group B1 and patients who developed additional
morbidities and/or mortality during their ICU stay were
grouped as Group B2.
4. Blood sampling and processing
At time of arrival to ED, prior to any manipulations or apply-
ing lines of treatment, 5 ml peripheral blood sample was
obtained under complete aseptic conditions into EDTA-
containing tubes. Blood samples were centrifuged at 1600g
for 10 min, and plasma was removed, with great care taken
not to disturb the cell pellet, placed in clean plain polypropy-
lene tubes, and stored at 80 C till be processed. Blood sam-
ples of the healthy controls were also collected and processed
in the same way.
5. Preparation and quantification of plasma DNA
5.1. DNA isolation from plasma
Circulating cell-free mitochondrial DNA (ccf-mtDNA) was
extracted from plasma by use of a QIAamp Blood Kit (Qiagen
Plasma mitochondrial DNA at admission 567GmbH) according to manufacturer’s instruction [9]. Samples
were thawed on ice and were then mixed briefly by vortex,
and then 100 ll of plasma was mixed with 100 ll of PBS, fol-
lowed by brief vortex. Diluted plasma was centrifuged at 700g
at 4 C for 5 min, and the supernatant (190 ll) was carefully
pipetted taking care not to touch any pellets or the bottom
of the tubes with pipette tips. The obtained supernatant was
further centrifuged at 18,000g at 4 C for 15 min, and the
resulting supernatant (170 ll) was obtained taking care of
supernatant contamination because contamination of cells, cell
debris, or pellets into supernatant might lead to a significant
change of the results.
The obtained supernatant was processed for DNA isola-
tion. In brief, samples were incubated with lysis buffer
(included in the kit) and proteinase K at 56 C for 15 min.
At the final step of DNA isolation, DNA was eluted in
200 ll of elution buffer (included in the kit). For the quantita-
tive real-time polymerase chain reaction (qPCR) assay, the
DNA solution was further diluted 10 times with nuclease-
free deionized, distilled H2O.
5.2. Primers and qPCR
DNA level in diluted samples was measured by SYBR Green
dye-based qPCR assay using a PRISM 7300 sequence detec-
tion system (Applied Biosystems). The primer sequences were
as follows: human NADH dehydrogenase 1 gene (mtDNA):
forward 50-ATA CCC ATG GCC AAC CTC CT-30, reverse
50-GGG CCT TTG CGT AGT TGT AT-30 [9]. Bacterial 16S
ribosomal RNA: forward 50-CGT CAG CTC GTG TTG
TGA AA-30, reverse 50-GGC AGT CTC CTT GAG TTC C-
30 [3]. Plasmid DNA with complementary DNA sequences
for human mtDNA was obtained from ORIGENE
(SC101172), and plasmid DNA with complementary DNA
sequences for human nuclear DNA was obtained from Sino
Biological. DNA solutions were diluted in 10-fold serial dilu-
tions and used as standards. Thermal profile for detecting
mtDNA was carried out as follows: an initiation step for
2 min at 50 C is followed by a first denaturation step for
10 min at 95 C and a further step consisting of 40 cycles for
15 s at 95 C and for 1 min at 60 C. All samples were analyzed
in duplicate, and a no-template control was included in every
analysis. mtDNA levels in all of the plasma analyses were
expressed in copies/ll of plasma [10].
5.3. Study outcome
Primary outcome: Primary outcome is the frequency of sur-
vival and additional morbidity rate.
Secondary outcome: Secondary outcome is the predictability
of at admission plasma ccf-mtDNA level for the prediction
of possibility of survival and development of additional
morbidity.
5.4. Statistical analysis
Sample size was calculated using the standard nomogram pro-
posed by Kraemer and Theimann [11] and a sample size of 30
patients was determined to be sufficient to detect a difference
at the 5% significance level and give the trial 60% power[12]. Sample size and power were re-calculated and assured
using Power and Sample Size Calculation Software program
provided by Department of Biostatistics, Vanderbilt Univer-
sity. Obtained data were presented as mean ± SD, ranges,
numbers and ratios. Results were analyzed using One-way
ANOVA with post hoc Tukey HSD Test and Chi-square test
(X2 test). Possible relationships were investigated using Pear-
son linear regression. Sensitivity and specificity of ccf-
mtDNA as predictor for patients’ outcome (survivors or
non-survivors) were evaluated using the receiver operating
characteristic (ROC) curve analysis judged by the area under
the curve (AUC). Statistical analysis was conducted using
the SPSS (Version 15, 2006) for Windows statistical package.
P value <0.05 was considered statistically significant.
6. Results
The study included 92 trauma patients admitted to ED; details
of patients’ demographic, clinical and trauma-related data are
shown in Table 1.
Thirty-one patients were managed conservatively or surgi-
cally and were admitted to surgical ward without need for
ICU admission and their blood samples were discarded and
excluded from the study. Sixty-one patients required admission
to ICU (Group B), and 12 patients underwent surgical interfer-
ence after stabilization of general condition and full investiga-
tions and were admitted to surgical ICU for their immediate
PO observation. Nine patients showed hemodynamic deterio-
ration and underwent emergency surgical interference and
were admitted to surgical ICU after surgery. Seven patients
underwent surgical interference and were initially admitted to
surgical ward but developed complications necessitated their
shift to ICU. Fifteen patients had surgical interference and
were admitted immediately to ICU for their PO care. Eighteen
patients were hemodynamically unstable on arrival to ER with
a mean SBP of 73.6 ± 3.1; range: 68–78 mmHg due to hemor-
rhage secondary to inflected trauma and were admitted imme-
diately to surgical ICU for preoperative preparation and
underwent emergency surgery and continued their PO care
period at ICU.
Twenty-seven patients (44.3%) passed smooth ICU stay
free of morbidity and were discharged alive without wound
related complication (Group B1), while 34 patients developed
additional morbidities during their ICU stay (Group B2) for a
total postoperative morbidity rate of 55.7%. Nineteen patients
(31.1%) developed septic morbidities, 13 patients (21.3%)
developed ARDS and two patients (3.3%) had acute myocar-
dial infarction (AMI). Fifty patients passed their additional
morbidities successfully and were discharged from ICU alive
for a total survival rate of trauma patients admitted to ICU
of 82%. Unfortunately, 11 patients died secondary either to
failure to respond to supportive measures for the resultant
pathology secondary to inflected trauma and PO decompensa-
tion or to their developed additional morbidities. Both patients
with AMI, 5 patients with ARDS and 4 patients with sepsis
had died for a mortality rate of 18% during ICU stay (Table 2).
Mean ISS was significantly higher in patients developed
septic complications and ARDS compared to those passed
smooth ICU without additional morbidities (Group B1), but
with non-significantly higher ISS score in ARDS patients
compared to patients developed sepsis. Mean ISS was
Table 1 At admission patients’ data.
Data Findings
Age (years) Strata <20 years 16 (15.7%)
20–29 29 (28.4%)
30–39 23 (22.5%)
40–49 15 (14.7%)
50–59 12 (12.7%)
P60 6 (5.9%)
Total Number 102 (100%)
Mean (±SD) 35.3 ± 14.1 (15–74)
Gender Males 73 (71.6%)
Females 29 (28.4%)
Time lapsed between trauma (minutes) Strata <60 78 (76.5%)
60–120 19 (18.6%)
>120 5 (4.9%)
Total Mean (±SD) 56.8 ± 27.7 (20–140)
Site and multiplicity of injury Solitary injury Head and neck 9 (8.8%)
Chest 18 (17.6%)
Abdomen 32 (31.4%)
Extremities 14 (13.7%)
Multiple body trauma 29 (28.5%)
Type and cause of trauma Penetrating (n= 61; 59.8%) Bullet Single 5 (4.9%)
Multiple 4 (3.9%)
Gunshots 7 (6.9%)
Knives Single 4 (3.9%)
Multiple 6 (5.8%)
Car accident 26 (25.4%)
Sharp objects 9 (8.8%)
Blunt (n= 41; 40.2%) Car accident 19 (18.6%)
Fall from height 12 (11.8%)
Crush injury 10 (9.8%)
Mortality at ED according to multiplicity of truma Solitary body trauma 6 (5.8%)
Multiple body trauma 4 (3.9%)
Total 10 (9.8%)
Data are shown as numbers and mean ± SD; percentages and ranges are in parenthesis.
Table 2 Outcome of patients admitted to ICU.
Group Survived Died Total
Group A1 (Free of additional morbidities) 27 (44.3%) 0 27 (44.3%)
Group A2 (Developed additional morbidities) Sepsis 15 (24.5%) 4 (6.6%) 19 (31.1%)
ARDS 8 (13.1%) 5 (8.2%) 13 (21.3%)
AMI 0 2 (3.3%) 2 (3.3%)
Total 50 (82%) 11 (18%) 61 (100%)
Data are presented as numbers; percentages are in parenthesis; ARDS: Adult respiratory distress syndrome; AMI: Acute myocardial infarction.
568 A.A. Mohamed et al.non-significantly higher in patients developed AMI compared
to patients of group B1, but was non-significantly lower
compared to those developed sepsis or ARDS. Mean plasma
ccf-mtDNA levels of patients of group B were significantly
higher compared to control level (Group A). However,
patients of Group B1 had significantly lower plasma
ccf-mtDNA compared to patients of Group B2. Patients devel-
oped ARDS had significantly higher plasma ccf-mtDNA levels
compared to patients developed sepsis or AMI with signifi-
cantly higher levels in patients developed sepsis compared to
patients developed AMI (Table 3).At admission plasma ccf-mtDNA levels showed positive
significant correlation with the frequency of additional mor-
bidities development (r= 0.538, p= 0.0006). The odds ratio
for relative risk for development of additional morbidities in
patients had high plasma ccf-mtDNA level was 26.3455
(95% CI is 1.4774–469.791; Z= 2.226, p= 0.026) (Fig. 1).
Mean at admission plasma ccf-mtDNA levels in survivors
(4011.6 ± 3885 copies/ll) was significantly (p= 0.045) lower
compared to non-survivors (11040.9 ± 9116 copies/ll)
(Fig. 2). The odds ratio for relative risk for death of patients
had high plasma ccf-mtDNA level was 4.0806 (95% CI is
Table 3 Mean at admission plasma ccf-mtDNA levels and ISS scores of enrolled patients’ categorized according to outcome.
Group Plasma ccf-mtDNA ISS
Level P value Level P value
Control (Group A; n= 10) 879 ± 227.6 0
Group B1 (Free of additional morbidities; n= 27) 1428.9 ± 463.2 P1 = 0.0005 15.9 ± 4.7
Group B2 (Developed additional morbidities) Sepsis (n= 19) 4515.8 ± 2040.8 P1 = 0.0006
P2 = 0.00006
21 ± 7.6 P2 = 0.015
ARDS (n= 13) 14892.3 ± 8015.4 P1 = 0.0008
P2 = 0.0009
P3 = 0.004
24.1 ± 2.8 P2 = 0.001
P3 > 0.05
AMI (n= 2) 2025 ± 106.1 P1 = 0.0007
P2 = 0.0009
P3 = 0.001
P4 = 0.001
20.5 ± 4.9 P2 > 0.05
P3 > 0.05
P4 > 0.05
Total 5279.2 ± 6436.1 P1 = 0.0003 19.4 ± 6.3
Data are presented as mean ± SD; ARDS: Adult respiratory distress syndrome; AMI: Acute myocardial infarction; P1: significance versus
control levels; P2: significance versus levels of patients of group B1; P3: significance versus levels of patients developed sepsis; P4: significance
versus levels of patients developed ARDS.
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Figure 1 Cumulative hazard for development of additional
morbidities in patients had at admission high mtDNA level.
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Figure 2 Mean (±SD) plasma mtDNA levels estimated in
survivors compared to non-survivors.
Plasma mitochondrial DNA at admission 5690.2588–64.34; Z= 0.999, p> 0.05) (Fig. 3). ROC curve anal-
ysis showed significantly small area under curve for pre-
dictability of at admission plasma ccf-mtDNA for survival
indicating high sensitivity of high plasma levels as a predictor
for ICU mortality (Fig. 4).7. Discussion
The current study detected a significantly higher plasma
ccf-mtDNA levels in acute trauma patients admitted to ICU
compared to levels estimated in control healthy volunteers.
Patients developed additional morbidities during ICU stay
were found to have significantly higher levels compared to
both levels of controls and patients who did not develop addi-
tional morbidities. Moreover, estimated ccf-mtDNA levels
were significantly higher in patients developed ARDS than in
patients who developed septic morbidities and acute myocar-
dial infarction (AMI) with significantly higher levels in patients
developed septic morbidities than in patients developed AMI.
These findings go in hand with Simmons et al. [13] who
reported that patients with SIRS had significantly increased
ccf-mtDNA levels in all sequences examined and in patients
who developed multiple-organ dysfunction (MOD) than
patients who did not develop MOD. Gu et al. [14] also found
median plasma ccf-mtDNA was significantly higher in trauma
At admission plasma mtDNA level (copies/ul)
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Figure 3 Cumulative hazard for mortality in patients had at
admission high mtDNA level.
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Figure 4 ROC curve analysis for predictability of at admission
high mtDNA level for mortality of enrolled patients.
570 A.A. Mohamed et al.patients than in healthy controls. Recently, in 2016, Clementi
et al. [15] detected significantly higher levels of cfDNA in septic
patients than controls and in septic patients who developed
acute kidney injury (AKI) requiring renal replacement therapy
than in patients who did not develop AKI.
Relative risk (RR) for patients had at admission high
plasma ccf-mtDNA to develop additional morbidities was high
and odd ratio (OR) was significant with curve showingcondensation of free patients in narrow low range indicating
its predictability for future morbidities as specific predictor.
Concerning mortality, ROC curve analysis showed high sensi-
tivity to predict mortality with narrow AUC that was signifi-
cantly smaller compared to the null hypothesis that
AUC= 0.5 is nonsense.
In line with the predictability of high plasma ccf-mtDNA
for morbidity and mortality, Kung et al. [16] concluded that
plasma ccf-mtDNA has potential use for predicting outcome
in septic patients arriving at ED and on admission plasma
ccf-mtDNA level is a more powerful predictor for fatality of
severe septic patients than on admission lactate concentration
or SOFA scores. Yamanouchi et al. [17] reported that in
trauma patients, day-1 concentrations of ccf-mtDNA signifi-
cantly correlated with the maximal levels of creatinine phos-
phokinase and were significantly higher in non-survivors
compared with survivors of trauma. Simmons et al. [13] found
patients with above-median ccf-mtDNA levels had a signifi-
cantly elevated RR for mortality and concluded that plasma
ccf-mtDNA is associated with the evolution of SIRS, MOD,
and mortality in severely injured human subjects.
Gu et al. [14] also reported that regression analysis revealed
that the plasma ccf-mtDNA was an independent predictor for
post-traumatic SIRS and ROC analysis demonstrated that a
high plasma ccf-mtDNA level predicted post-traumatic SIRS
with sensitivity and specificity of 67% and 76%, respectively.
Nakahira et al. [18] assessed analyses of ccf-mtDNA levels in
two prospective observational cohort studies of ICU patients
and concluded that increased ccf-mtDNA levels are associated
with ICU mortality and improved risk prediction in ICU
patients and it could serve as a viable plasma biomarker for
ICU patients.
Yang et al. [19] reported that the concentration of
ccf-mtDNA in blood was found to be a prognostic indicator
for ICU mortality in patients with severe sepsis. Recently, in
2016, Clementi et al. [15] documented that ccf-mtDNA can
be considered as a good prognostic marker of clinical outcome
in septic patients with its increased levels are associated with
poor outcome and correlate with caspase-3, interleukin 6 and
18 levels.
Multiple studies tried to explore the underlying mechanisms
for development of additional morbidities in trauma patients
with high plasma ccf-mtDNA; Zhang et al. [3] reported that
injury releases mitochondrial damage-associated molecular
patterns (DAMPs) including ccf-mtDNA into the circulation;
it activates human poly-morphonuclear neutrophils (PMN)
and promotes PMN calcium ion flux and phosphorylation of
mitogen-activated protein kinases, thus leading to PMN
migration and degranulation in vitro and in vivo and elicit
neutrophil-mediated organ injury, thus creating a sepsis-like
state and concluded that the release of such mitochondrial
‘enemies within’ by cellular injury is a key link between
trauma, inflammation and SIRS.
Gomez et al. [20] found that in trauma patients who carry
the C-allele, T4216C polymorphism in the NADH dehydroge-
nase 1 gene was less able to generate the cellular energy neces-
sary to mount an effective immune response relative to carriers
of the T-allele and showed significantly increased risk for sepsis
complicated by MOD or septic shock as well as death. Lorente
et al. [21] found that septic patients with ccf-mtDNA hap-
logroup JT showed increased 30-day and 6-month survival
and concluded that this finding may be due to single nucleotide
Plasma mitochondrial DNA at admission 571polymorphism defining the whole haplogroup JT and not
separately for J or T sub-haplogroups. Ferna´ndez-Ruiz et al.
[22] found that exposure of monocyte to ccf-mtDNA induces
endotoxin tolerance which is characterized by decreased pro-
duction of cytokines in response to pro-inflammatory stimuli.
In the current study, blood samples were obtained at time
of ED admission and prior to manipulation; in line with such
timing Kung et al. [16] found on admission median plasma
ccf-mtDNA and nuclear DNA levels were significantly higher
in severe septic patients compared to controls and Yamanou-
chi et al. [17] also reported that in patients with trauma,
concentrations of ccf-mtDNA peaked on the day-1 of admis-
sion. Moreover, Ren et al. [7] reported that positive plasma
ccf-mtDNA samples were higher 1–6 h after injury than
24–48 h and 60–90 h.
8. Conclusion
High at ED admission plasma ccf-mtDNA levels could predict
development of additional morbidities during ICU stay of
acute trauma patients and showed high sensitivity for predic-
tion of their survival. Very high plasma ccf-mtDNA levels
could predict patients liable to develop ARDS.9. Limitation of the study
One of limitation points was inclusion of trauma patients only;
the obtained results needed to be adjusted for patients admit-
ted to ICU, irrespective of diagnosis. Another point was the
cost of PCR estimation of plasma ccf-mtDNA to advise its
wide spread applicability.Conflict of interest
No conflict of interest.
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